Pump Speed Optimization in Patients Implanted With the HeartMate 3 Device

Background

Pump speed optimization in patients implanted with a ventricular assist device represents a major challenge during the follow-up period. We present our findings on whether combined invasive hemodynamic ramp tests and cardiopulmonary exercise testing (CPX) can help optimize patient management.

健康支持性环境对四川农村人群的不同血压水平的影响分析

目的 探讨健康支持性环境中的不同特征变量对四川省农村人群的不同血压水平的影响。方法 采用多阶段整群抽样的方法，随机抽取四川省7个县（区）8400名的18岁以上常住居民为调查对象。问卷调查一般人口学特征、身体活动行为特征和环境等信息。采用标准方法测量身高、体重、腰围和血压。采用无序多分类logistic回归分析。结果 本调查人群中共检出正常高值血压者4270例，检出率为50.83%，标化率为37.02%，平均年龄（56.22±14.89）岁；高血压患者1498例，检出率为17.83%，标化率为7.92%，平均年龄（65.26±11.28）岁。无序多分类logistic回归结果显示，住宿环境好、获得运动方面的健康信息和参与中等强度活动150Symbol~A@300min/周是正常高值血压和高血压人群的共同保护因素；住宿便利（OR=0.789, 95%CI:0.649~0.958, P=0.017）、医疗服务可及性便利（OR=0.686, 95%CI:0.509~0.924, P=0.013）、对健身步道和健身广场满意为高血压人群的保护因素。结论 多途径合理构建健康支持性环境，对农村正常高值血压者和高血压患者具有保护作用，对遏制农村高血压的流行现状起到一定作用。     

腹腔镜胆囊切除术患者围术期多项血清应激状态相关指标变化观察

目的:分析腹腔镜胆囊切除术的临床疗效,分析其对血清应激指标的影响。方法:将160例来我院行胆囊切除术的患者随机分为两组,对照组和观察组各80例。对照组采用开腹胆囊切除术,观察组则采用腹腔镜胆囊切除术。比较两组间手术时间、术中出血量、肠功能恢复时间以及住院天数差异,比较治疗前后两组患者间血清应激相关指标皮质醇(COR)、去甲肾上腺素(NE)、促肾上腺皮质激素(ACTH)、多巴胺(DA)以及胰岛素(INS)、三碘甲状腺原氨酸(T3)、甲状腺素(T4)、促甲状腺激素释放激素(TSH)水平差异。结果:观察组患者手术时间、术中出血量、肠功能恢复时间以及住院天数均显著少于对照组(P<0.05)。血清COR、NE、ACTH、DA和INS、T3水平在围手术期均发生了显著变化,各项指标均在胆囊分离时就明显升高,术后24 h开始下降(P<0.05);术后观察组上述指标均显著低于对照组(P<0.05)。结论:腹腔镜胆囊切除术对机体应激反应影响小于开腹手术,更利于患者术后康复。     

探究培美曲塞与多西他赛在晚期非小细胞肺癌靶向治疗失败后挽救化疗中的临床疗效

目的 研究培美曲塞与多西他赛在晚期非小细胞肺癌靶向治疗失败后挽救化疗中的应用效果。方法 筛选2018 年1 月～2020 年1 月本院的60 例晚期非小细胞肺癌靶向治疗失败后挽救化疗的患者作为研究对象，依据患者选择的药物种类分为观察组和对照组，每组各30 例，对照组采用多西他赛治疗，观察组予以培美曲塞治疗，对比分析两组的近期治疗效果、生存质量评分和毒副反应发生情况。结果 观察组病症控制率为66.67%，对照组病症控制率为36.67%，观察组病症控制效果更好；观察组生存质量评分为（65.2±3.4）分，对照组生存质量评分为（51.7±4.6）分，两组比较差异有统计学意义（t=12.926，P=0.000）；观察组各项毒副反应发生率均低于对照组，差异有统计学意义（P＜0.05）。结论 在晚期非小细胞肺癌靶向治疗失败后进行挽救化疗中选用培美曲塞有更好的治疗效果，可以较好的进行临床治疗，改善患者的生活质量，且产生的毒副反应较少，在实际临床中的应用价值较高。     

Aminotransferases During Treatment Predict Long-Term Survival in Patients With Autoimmune Hepatitis Type 1: A Landmark Analysis

1. Download : Download high-res image (187KB)
2. Download : Download full-size image

     

Implementation strategies for the first licensed dengue vaccine: A meeting report

Dengue vaccination would enhance the control of dengue, one of the most frequent vector-borne viral diseases globally. CYD-TDV is the first dengue vaccine to be licensed, but global uptake has been hampered due to its use being limited to seropositive persons aged 9 years and above, and the need for a 3-dose schedule. The Partnership for Dengue Control (PDC) organized a meeting with key opinion leaders and stakeholders to deliberate on implementation strategies for the use of CYD-TDV. New data have emerged that support the shortening of the primary schedule from a 3 to 2 dose schedule, extending the age range below 9 to 6 years of age, and expanding the indication from endemic populations to also include travelers to endemic areas. Cost-effectiveness may improve with the modified 2-dose regimen and with multiple testing. Strategies to implement a dengue vaccination program have been developed, in particular school-based strategies. A range of delivery scenarios can then be considered, using various settings for each step of the intervention. However, several challenges remain, including communication about limiting the use of this vaccine to seropositive individuals only. Affordability will vary from country to country, as will government commitment and community acceptance. Well-tailored communication strategies that target key stakeholders are expected to make up a significant part of any future dengue vaccination program.